HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia

Files in This Item:
AmJHematol92_902.pdf337.72 kBPDFView/Open
SupplementaryTable1(clean_version).docxSupplementary Table 1417.22 kBMicrosoft Word XMLView/Open
SupplementaryTable2(clean_version).docxSupplementary Table 2380.95 kBMicrosoft Word XMLView/Open
SupplementaryTable3(clean_version).docxSupplementary Table 3364.24 kBMicrosoft Word XMLView/Open
SupplementaryTable4(clean_version).docxSupplementary Table 4325.3 kBMicrosoft Word XMLView/Open
SupplementaryTable5(clean_version).docxSupplementary Table 5234.18 kBMicrosoft Word XMLView/Open
SupplementaryTable6(clean_version).docxSupplementary Table 6291.2 kBMicrosoft Word XMLView/Open
online_supplementary_material(clean_version).docxSupplementary Information6.45 MBMicrosoft Word XMLView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/71411

Title: Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia
Other Titles: Clinical impact of pre-transplant use of multiple tyrosine kinase inhibitors on the outcome of allo-HSCT for CML
Use of multiple TKIs before allo-HSCT for CML
Authors: Kondo, Takeshi Browse this author →KAKEN DB
Nagamura-Inoue, Tokiko Browse this author
Tojo, Arinobu Browse this author
Nagamura, Fumitaka Browse this author
Uchida, Naoyuki Browse this author
Nakamae, Hirohisa Browse this author
Fukuda, Takahiro Browse this author
Mori, Takehiko Browse this author
Yano, Shingo Browse this author
Kurokawa, Mineo Browse this author
Ueno, Hironori Browse this author
Kanamori, Heiwa Browse this author
Hashimoto, Hisako Browse this author
Onizuka, Makoto Browse this author
Takanashi, Minoko Browse this author
Ichinohe, Tatsuo Browse this author
Atsuta, Yoshiko Browse this author
Ohashi, Kazuteru Browse this author
Issue Date: Sep-2017
Publisher: John Wiley & Sons
Journal Title: American journal of hematology
Volume: 92
Issue: 9
Start Page: 902
End Page: 908
Publisher DOI: 10.1002/ajh.24793
PMID: 28543934
Abstract: Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with chronic myelogenous leukemia in the chronic phase (CML-CP), and outcomes of TKI treatment for patients with CML-CP have been excellent. Since multiple TKIs are currently available, second-line or third-line TKI therapy is considered for patients who are intolerant of or resistant to the previous TKI treatment. Therefore, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered only for patients with disease progression or for patients after treatment failure with multiple TKIs. To reflect the current clinical situation of patients with CML-CP, we tried to clarify whether prior TKI treatment affects the outcome of allo-HSCT. Data from 237 patients for whom the number of pretransplant TKIs varied from one to three were used for analysis. Before allo-HSCT, 153 patients were treated with one TKI, 49 patients were treated with two TKIs and 35 patients were treated with three TKIs. In addition to conventional risk factors, i.e., disease status at transplantation and patient's age, the use of three TKIs before transplantation was identified as a significant adverse factor for prognosis. Nonrelapse mortality rate was higher in patients treated with three TKIs than in patients treated with one or two TKIs. Our results suggest that allo-HSCT could be considered for young patients with CML-CP who manifest resistance to second-line TKI therapy and who have an appropriate donor.
Rights: This is the peer reviewed version of the following article: Kondo T, Nagamura-Inoue T, Tojo A, et al. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. Am J Hematol. 2017;92:902–908., which has been published in final form at https://doi.org/10.1002/ajh.24793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Type: article (author version)
URI: http://hdl.handle.net/2115/71411
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 近藤 健

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University